乳がんリキッドバイオプシー市場：バイオマーカー別、エンドユーザー別-2025-2030年の世界予測

乳がんリキッドバイオプシー市場は、2023年に4億9,429万米ドルと評価され、2024年には5億8,992万米ドルに達すると予測され、CAGR 19.44%で成長し、2030年には17億1,415万米ドルに達すると予測されています。

乳がんリキッドバイオプシー市場は、がんの早期発見、モニタリング、個別化治療を可能にする低侵襲検査に焦点を当てた急速に発展している分野です。この手法では、患者の血液中の循環腫瘍DNA（ctDNA）を分析することで、腫瘍の動態を包括的に把握することができます。リキッドバイオプシーが必要とされる主な要因には、乳がんの世界の有病率の増加や、侵襲性や潜在的合併症といった従来の生検の限界があります。リキッドバイオプシーの用途は、早期発見から治療効果のモニタリング、再発の可能性の特定まで多岐にわたる。最終用途分野には主に病院、診断研究所、研究機関が含まれます。

市場成長は、ゲノミクスと精密医療における技術的進歩、がん早期発見の利点に対する意識の高まり、非侵襲的診断技術へのシフトに影響されます。潜在的な成長機会は新興市場にあり、そこではヘルスケア支出の増加と意識の高まりが成長見通しを増幅させています。さらに、バイオテクノロジー企業と研究機関との提携により、技術革新が加速し、こうした先端診断薬へのアクセスが向上する可能性もあります。しかし、高コスト、規制上のハードル、従来の組織生検と比べた感度の限界といった課題が残っており、市場の拡大を抑制する可能性があります。

技術革新のための最良の分野には、リキッドバイオマーカー検出技術の感度と特異度の向上、リキッドバイオプシーデータの予測分析と解釈を強化するための人工知能の統合などがあります。複数のがんの早期発見と新規バイオマーカーの探索に重点を置いた調査が競争優位性をもたらす可能性があります。市場は非常にダイナミックで断片化されており、既存企業や新興企業による競合が激しいため、企業は研究開発や戦略的提携に投資することが重要です。企業は、コスト構造の最適化と規制経路の簡素化に注力し、採用率を高める必要があります。急速な技術革新と複雑な規制を特徴とする市場において、競争上の優位性を維持し成長を促進するためには、戦略立案における敏捷性と先見性が不可欠です。

市場力学：急速に進化する乳がんリキッドバイオプシー市場の主要市場インサイトを公開

乳がんリキッドバイオプシー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の乳がん罹患率の上昇
  • 非侵襲的乳がん治療に対する需要の増加
  • リキッドバイオプシー研究開発への資金提供の可能性
• 市場抑制要因
  • 乳がんリキッドバイオプシーの高コスト
• 市場機会
  • 乳がんリキッドバイオプシーの早期発見における技術の進歩
  • 乳がんリキッドバイオプシー試薬承認の増加
• 市場の課題
  • 厳しい規制の問題と不十分な償還政策

ポーターの5つの力：乳がんリキッドバイオプシー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：乳がんリキッドバイオプシー市場における外部からの影響の把握

外部マクロ環境要因は、乳がんリキッドバイオプシー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析乳がんリキッドバイオプシー市場における競合情勢の把握

乳がんリキッドバイオプシー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス乳がんリキッドバイオプシー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、乳がんリキッドバイオプシー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨乳がんリキッドバイオプシー市場における成功への道筋を描く

乳がんリキッドバイオプシー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で乳がん罹患率が上昇
    • 非侵襲性乳がん治療の需要増加
    • 液体生検の研究開発のための資金の入手可能性
  • 抑制要因
    • 乳がんリキッドバイオプシーのコストが高い
  • 機会
    • 乳がんリキッドバイオプシーの早期検出における技術的進歩
    • 乳がんリキッドバイオプシー試薬承認の増加
  • 課題
    • 厳しい規制問題と不十分な償還ポリシー
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 乳がんリキッドバイオプシー市場バイオマーカー

• 遊離DNA
• 循環腫瘍細胞
• 細胞外小胞

第7章 乳がんリキッドバイオプシー市場：エンドユーザー別

• 病院および医師の検査室
• リファレンスラボ

第8章 南北アメリカの乳がんリキッドバイオプシー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の乳がんリキッドバイオプシー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの乳がんリキッドバイオプシー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adaptive Biotechnologies Corporation
• Bio-Rad Laboratories, Inc.
• Biocept, Inc.
• Biodesix, Inc.
• Epic Sciences Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fluxion Biosciences Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• NeoGenomics Laboratories, Inc.
• Qiagen N. V. by Thermo Fisher Scientific Inc.
• Sysmex Corporation
• The Menarini Group

LIST OF FIGURES

• FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
• FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The Breast Cancer Liquid Biopsy Market was valued at USD 494.29 million in 2023, expected to reach USD 589.92 million in 2024, and is projected to grow at a CAGR of 19.44%, to USD 1,714.15 million by 2030.

The breast cancer liquid biopsy market is a rapidly evolving sector focused on minimally invasive tests enabling early cancer detection, monitoring, and personalized treatment. This method involves analyzing circulating tumor DNA (ctDNA) in a patient's blood, offering a comprehensive view of tumor dynamics. Key factors driving its necessity include the increasing global prevalence of breast cancer and the limitations of traditional biopsies, such as invasiveness and potential complications. Applications of liquid biopsy span from early detection to monitoring treatment efficacy and identifying potential relapse, thus enhancing precision and personalization in patient care. End-use segments primarily include hospitals, diagnostic laboratories, and research institutes.

Market growth is influenced by technological advancements in genomics and precision medicine, increasing awareness of early cancer detection benefits, and a shift towards non-invasive diagnostic techniques. Potential opportunities lie in emerging markets, where increasing healthcare expenditure and heightened awareness amplify growth prospects. Additionally, partnerships between biotech firms and research institutions could accelerate innovation and improve accessibility to these advanced diagnostics. However, challenges remain in the form of high costs, regulatory hurdles, and limited sensitivity compared to traditional tissue biopsies, potentially restraining market expansion.

The best areas for innovation include improving the sensitivity and specificity of liquid biomarker detection techniques and integrating artificial intelligence to enhance predictive analytics and interpretation of liquid biopsy data. Research focused on multi-cancer early detection and the exploration of new biomarkers could provide competitive advantages. The market is highly dynamic and fragmented with strong competition among established players and rising startups, making it crucial for companies to invest in R&D and strategic collaborations. Businesses should focus on optimizing cost structures and simplifying regulatory pathways to enhance adoption rates. In a market characterized by rapid technological updates and regulatory complexities, agility and foresight in strategic planning are vital for sustaining competitive advantage and fostering growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of breast cancer worldwide
  • Increasing demand for non-invasive breast cancer treatment
  • Availability of funding for liquid biopsy R&D
• Market Restraints
  • High cost of breast cancer liquid biopsy
• Market Opportunities
  • Technological advancements in early-stage detection of breast cancer liquid biopsy
  • Increasing breast cancer liquid biopsy reagent approvals
• Market Challenges
  • Stringent regulatory issues and poor reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Market

A strategic analysis of the Breast Cancer Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., NeoGenomics Laboratories, Inc., Qiagen N. V. by Thermo Fisher Scientific Inc., Sysmex Corporation, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles.
• Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of breast cancer worldwide
    • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
    • 5.1.1.3. Availability of funding for liquid biopsy R&D
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of breast cancer liquid biopsy
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
    • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Market, by Biomarker

• 6.1. Introduction
• 6.2. Cell-free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals & Physician Laboratories
• 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptive Biotechnologies Corporation
• 2. Bio-Rad Laboratories, Inc.
• 3. Biocept, Inc.
• 4. Biodesix, Inc.
• 5. Epic Sciences Inc.
• 6. Exact Sciences Corporation
• 7. F. Hoffmann-La Roche Ltd.
• 8. Fluxion Biosciences Inc.
• 9. Guardant Health, Inc.
• 10. Illumina, Inc.
• 11. Johnson & Johnson Services, Inc.
• 12. NeoGenomics Laboratories, Inc.
• 13. Qiagen N. V. by Thermo Fisher Scientific Inc.
• 14. Sysmex Corporation
• 15. The Menarini Group